Sandbox:AA

Aysha's sandbox

Common complications

Common complications
Pathogen	Complications
Group A Streptococcus	Suppurative complications Tonsillar abscess Sinusitis Otitis media Necrotizing fasciitis Meningitis Jugular vein thrombophlebitis Non suppurative complications Acute rheumatic fever (ARF) Scarlet fever Streptococcal toxic shock syndrome Acute glomerulonephritis Pediatric autoimmune neuropsychiatric disorder associated with group A streptococci (PANDAS)
Influenza	Pneumonia Encephalitis Aseptic meningitis Guillain barre syndrome Transverse myelitis Myositis and rhabdomyolysis
Adenovirus	Laryngotracheitis Bronchitis Pneumonia Otitis media Meningoencephalitis Hepatitis Myocarditis Nephritis Neutropenia Disseminated intravascular coagulation
Cocksackie A virus	Aseptic meningitis Myocarditis Acute flaccid paralysis Conjunctival ulceration Brainstem encephalitis
Ebstein barr virus	Airway obstruction Splenic rupture X-linked lymphoproliferative disease Lymphomatoid granulomatosis
Less common complications
Gonococcus	Disseminated gonorrhea Meningitis Endocarditis
Diphtheria	Airway obstruction Myocarditis Polyneuropathies 10th cranial nerve disorder 9th cranial nerve disorder Peripheral motor neuropathy Diaphragm paralysis Neurogenic bladder dysfunction Acute renal failure Septicemia
Heamophilis influenza	Retropharyngeal abcess Epiglottitis
Fusobacterium necrophorum	Peritonsillar abscess Lemierre's syndrome
Parainfluenza virus	Retropharyngeal abcess Pneumonia

Pathogen	Complications
Diphtheria	A B C D
Gonococcus	A B C D
'	A B C D
Cocksackie A virus	A B C D
Ebstein barr virus	A B C D
Gonococcus	B C D
HIV	B C D

MRI syphilis 17628376

Among women the median prevalence of genital warts was 1.1% (range 0.8 to 2.3) across all jurisdictions, compared to 4.0% (range 2.9 to 4.7) for MSM and 4.9% (range 3.3 to 5.5) for MSW.

Varicella containing vaccines	Indications	Efficacy and immunogenicity	Recommended dose	Duration
Varicella vaccine (Varivax)	Approved for persons 12 months and older	Detectable antibody 97% of children 12 months through 12 years following 1 dose 99% of persons 13 years and older after 2 doses 70% to 90% effective against any varicella disease 90%-100% effective against severe varicella disease	2 doses separated by at least 4 weeks
Measles-mumps-rubella-varicella vaccine (ProQuad)	Approved for children 12 months through 12 years Do not use for persons 13 years and older	Efficacy of MMRV vaccine was inferred from that of MMR vaccine and varicella vaccine on the basis of noninferior immunogenicity Formal studies to evaluate the clinical efficacy of MMRV vaccine have not been performed	May be used for both first and second doses of MMR and varicella vaccines Minimum interval between doses is 3 months
Herpes zoster vaccine (Zostavax)	Approved for persons 50 years and older	Vaccine recipients 60 to 80 years of age had 51% fewer episodes of zoster Efficacy declines with increasing age Significantly reduces the risk of postherpetic neuralgia Reduces the risk of zoster 69.8% in persons 50 through 59 years of age	Single dose at age 60 years or older (whether or not they report a prior episode of herpes zoster)
New Herpes zoster vaccine (Shingrix)	Adults aged 50 years or older (first pivotal phase 3 trial) Adults aged 70 years and over (second pivotal phase 4 trial)	89% (95% confidence interval: 69– 97) efficacious in preventing PHN in people aged 70 years 91% (95% confidence interval: 76– 98) efficacious in people aged 50 years and over.	Two doses

| colspan="3" style="background: #4479BA; text-align: center;" | For individuals with penicillin allergy |- | style="padding: 5px 5px; background: #DCDCDC;" | Cephalexin, oral | style="padding: 5px 5px; background: #F5F5F5;" |

• 20 mg/kg/dose twice daily (max = 500 mg/dose)

| style="padding: 5px 5px; background: #F5F5F5;" |

• 10 days

|- | style="padding: 5px 5px; background: #DCDCDC;" | Cefadroxil, oral | style="padding: 5px 5px; background: #F5F5F5;" |

• 30 mg/kg once daily (max = 1 g)

| style="padding: 5px 5px; background: #F5F5F5;" |

• 10 days

|- | style="padding: 5px 5px; background: #DCDCDC;" | Clindamycin, oral | style="padding: 5px 5px; background: #F5F5F5;" |

• 7 mg/kg/dose 3 times daily (max = 300 mg/dose)

| style="padding: 5px 5px; background: #F5F5F5;" |

• 10 days

|- | style="padding: 5px 5px; background: #DCDCDC;" | Azithromycin, oral | style="padding: 5px 5px; background: #F5F5F5;" |

• 12 mg/kg once daily (max = 500 mg)

| style="padding: 5px 5px; background: #F5F5F5;" |

• 5 days

|- | style="padding: 5px 5px; background: #DCDCDC;" | Clarithromycin, oral | style="padding: 5px 5px; background: #F5F5F5;" |

• 7.5 mg/kg/dose twice daily (max = 250 mg/dose)

| style="padding: 5px 5px; background: #F5F5F5;" |

• 10 days

|- |}

Transmission	Clinical Presentation	Disease	Diagnosis		Mother to Child Transmission		Most Serious Complications
			Laboratory studies	Clinical Diagnosis	Vertical Transmission	Trans-vaginal transmission
Primarily sexually transmitted	Genital Dermatological Manifestation (e.g., ulcers, chancre, vesicles, warts, balanitis etc.)	HPV	✔	✔			Cervical Cancer
		Herpes simplex-2	✔	✔	✔	✔	Severe pruritis/discomfort
		Syphilis	✔	✔	✔		*Neurosyphilis *Cardiosyphilis
		Scabies	✔	✔			Moderate to Severe pruritis/discomfort
		Pubic lice	✔	✔			Moderate to Severe pruritis/discomfort
		Candidiasis (in males)		✔			Mild to moderate pruritis/discomfort
	Generalized Symptoms (e.g. constitutional symptoms	HIV	✔		✔		*Primary CNS Lymphoma *Immunosuppression (AIDS)
		Syphilis	✔	✔	✔		*Neurosyphilis *Cardiosyphilis
	Urogenital infections (e.g.,Vaginitis, Urethritis, Cervicitis, and PID)	Gonorrhea	✔	✔		✔	PID
		Chlamydia	✔	✔		✔	PID
		Syphilis	✔	✔	✔		*Neurosyphilis *Cardiosyphilis
		Mycoplasma genitalium	✔	✔	unknown	unknown	PID
		Trichomonas vaginalis	✔	✔			PID
Less frequently sexually transmitted	Generalized Symptoms (e.g. constitutional symptoms)	Zika Virus	✔		✔		Vertical transmission and Congenital abnormalities
		Hepatitis B	✔	✔	✔		Hepatocellular Carcinoma
		Hepatitis C	✔	✔	✔		Liver cirrhosis
	Urogenital Infections (e.g.,Vaginitis, Urethritis, Cervicitis, and PID)	Gardnerella vaginalis	✔	✔			Moderate to severe discomfort
		Candidiasis (in females)		✔			Moderate to severe pruritis/discomfort
		Ureaplasma urealyticum	✔	✔			Moderate to severe pruritis/discomfort

Postexposure prophylaxis

Active immunisation

Varicella vaccine is recommended for immunocompetent individuals exposed to varicella infection but did not receive full two dose course of vaccine previously

Passive immunisation

VZV immunoglobulin